Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al
2020 ◽
pp. annrheumdis-2020-217000
Keyword(s):
2020 ◽
pp. annrheumdis-2020-216983
Keyword(s):
Keyword(s):
Keyword(s):
2016 ◽
Vol 5
(33)
◽
pp. 1860-1862
Keyword(s):
Keyword(s):